Clinical trials: Patients With Chronic Migraine
Chronic Migraine, Headache
A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines
This study will evaluate the effectiveness of OnabotulinumtoxinA to prevent headaches in patients with Chronic Migraine.
- Trial name
- NCT01749423
- Testing
- OnabotulinumtoxinA
- Sponsor
- Allergan
Chronic Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age.
- Trial name
- REBUILD-2 (NCT04616326)
- Testing
- Galcanezumab
- Where
- 88 sites in United States, Denmark and 9 more
- Volunteers
- 312 people
- Sponsor
- Eli Lilly and Company
Chronic Migraine, Headaches
A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
- Trial name
- NCT01749410
- Testing
- onabotulinumtoxinA
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Allergan
Migraine Disorders
Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®
This study will prospectively assess long term heath related quality of life in chronic migraine patients currently being treated with OnabotulinumtoxinA for injection (BOTOX®) as standard of care.
- Trial name
- PREDICT (NCT02502123)
- Testing
- No Intervention
- Where
- 15 sites in Canada
- Volunteers
- 215 people
- Sponsor
- Allergan
Migraine Disorders
An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
This is an observational study to describe the long term use of Onabotulinumtoxin A (BOTOX®) as prescribed by the physician for headache prophylaxis in adults with chronic migraine. All treatment decisions lie with the physician.
- Trial name
- NCT01686581
- Testing
- botulinum toxin Type A
- Where
- 77 sites in Germany, Italy and 5 more
- Volunteers
- 641 people
- Sponsor
- Allergan
Migraine Disorders
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- PROMISE 2 (NCT02974153)
- Testing
- ALD403 (Eptinezumab)
- Where
- 144 sites in United States, Belgium and 11 more
- Volunteers
- 1,121 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
It will provide a first evaluation of efficacy, safety and tolerability of BGG492 in patients with non-chronic migraine having more than 3 and less than 12 migraine attacks per 4 weeks.
- Trial name
- NCT01617941
- Testing
- BGG492
- Sponsor
- Novartis Pharmaceuticals
Drug Resistant Epilepsy, Autism Spectrum Disorder
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
The goal of this observational study is to learn about the clinical and nutritional effectiveness of ketogenic diet (KD) in pediatric patients with genetic, neurological or metabolic conditions requiring KD.
- Conditions
- Drug Resistant Epilepsy, Autism Spectrum Disorder, Chronic Migraine, Brain Tumor, Pediatric
- Trial name
- NCT06309251
- Testing
- ketogenic diet (as per clinical practice)
- Where
- 3 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Danone Nutricia SpA Società Benefit
Migraine Disorder
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine
- Trial name
- PREVAIL (NCT02985398)
- Testing
- ALD403 (Eptinezumab)
- Where
- 20 sites in United States
- Volunteers
- 128 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine Headache
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)
This study consists of a 4-week screening period, a 24-week treatment period for all participants, followed by a 28-week treatment period extension (to 52 weeks in total) for a subset of at least 60 and up to 80 participants, and…
- Trial name
- NCT03557333
- Testing
- INP104
- Where
- 36 sites in United States
- Volunteers
- 360 people
- Sponsor
- Impel Pharmaceuticals
Low Back Pain, Migraine
Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.
- Conditions
- Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
- Trial name
- NCT00228605
- Testing
- OraVescent Fentanyl
- Where
- 38 sites in United States
- Volunteers
- 500 people
- Sponsor
- Cephalon
Migraine Disorders
BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine
This study will evaluate the efficacy and safety of BOTOX® (Botulinum Toxin Type A) compared with placebo as headache prophylaxis in Chinese participants with chronic migraine.
- Trial name
- NCT03193346
- Testing
- botulinum toxin Type A
- Sponsor
- Allergan
Migraine
Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- PRACTICE (NCT07690215)
- Volunteers
- 200 people
- Sponsor
- AbbVie
Migraine
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could…
- Trial name
- HER-MES (NCT03828539)
- Testing
- Erenumab, Topiramate
- Where
- 79 sites in Germany
- Volunteers
- 777 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Migraine
A Study With Intranasal Kinetic Oscillation Stimulation (KOS) in the Prevention of Chronic Migraine
An open pilot study, non-controlled, single center investigation.
- Trial name
- NCT05273151
- Testing
- KOS (Intranasal kinetic oscillation stimulation)
- Where
- 2 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- Chordate Medical
Migraine
Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
Migraine is a very common, neurological disorder, characterized by recurrent episodes of headache, potential progression to more frequent and severe attack patterns, and associated symptoms.
- Trial name
- COMIG (NCT04114630)
- Testing
- erenumab 70mg/mL
- Where
- 27 sites in Spain
- Sponsor
- Novartis Pharmaceuticals
Migraine Disorders
BOTOX® Prophylaxis in Patients With Chronic Migraine
This is a post authorization observational study to monitor the utilization practices and describe the safety profile of BOTOX® in clinical practice for the prophylactic treatment of headaches in adult patients with chronic…
- Trial name
- NCT01432379
- Testing
- botulinum toxin Type A
- Where
- 4 sites in Germany, Spain and 2 more
- Volunteers
- 1,168 people
- Sponsor
- Allergan
Chronic Migraine
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
- Trial name
- REGAIN (NCT02614261)
- Testing
- Galcanezumab
- Where
- 117 sites in United States, Argentina and 11 more
- Volunteers
- 1,117 people
- Sponsor
- Eli Lilly and Company
Migraine
Fremanezumab Managed Access Program for Pediatric Patients
This is a Managed Access Program (MAP) based on a licensed physician's unsolicited request on a compassionate basis. Specifically, this MAP is for male and female pediatric patients 6 to 17 years with a diagnosis of either…
- Trial name
- NCT03539393
- Testing
- Fremanezumab
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Chronic Migraine
Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA (BOTOX®) in adults with chronic migraine.
- Trial name
- NCT01833130
- Testing
- OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Allergan